1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neuroimmunology Drugs Market, By Product Type
5.1 Introduction
5.2 Monoclonal Antibodies
5.3 Small Molecules
5.4 Recombinant Protein
5.5 Cytokines
5.6 Lymphocytes
5.7 Other Product Types
6 Global Neuroimmunology Drugs Market, By Indication
6.1 Introduction
6.2 Multiple Sclerosis
6.3 Alzheimer’s Disease
6.4 Parkinson’s Disease
6.5 Myasthenia Gravis
6.6 Guillain-Barre Syndrome
6.7 Neuromyelitis Optica Spectrum Disorder
6.8 Amyotrophic Lateral Sclerosis
6.9 Chronic Inflammatory Demyelinating Polyradiculoneuropathy
6.10 Other Indications
7 Global Neuroimmunology Drugs Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Biogen
9.2 Hoffmann-La Roche Ltd
9.3 T3D Therapeutics
9.4 Novartis AG
9.5 Celgene Corp
9.6 Merck KGaA
9.7 Johnson & Johnson
9.8 Eisai Co Ltd
9.9 Sanofi
9.10 Actelion Pharmaceuticals Ltd.
9.11 ImmunoBrain Checkpoint
9.12 Lundbeck
9.13 Eli Lilly
9.14 AstraZeneca
9.15 UCB SA
9.16 AB Science S.A.
9.17 AstronauTx
9.18 Genetech Inc
9.19 Inflammasome Therapeutics
9.20 TauRX Therapeutics Ltd
List of Tables
Table 1 Global Neuroimmunology Drugs Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 3 Global Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 4 Global Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 5 Global Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 6 Global Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 7 Global Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 8 Global Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 9 Global Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 10 Global Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 11 Global Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 12 Global Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 13 Global Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 14 Global Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 15 Global Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 16 Global Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 17 Global Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 18 Global Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 19 North America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 20 North America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 21 North America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 22 North America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 23 North America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 24 North America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 25 North America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 26 North America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 27 North America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 28 North America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 29 North America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 30 North America Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 31 North America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 32 North America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 33 North America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 34 North America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 35 North America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 36 North America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 37 Europe Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 38 Europe Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 39 Europe Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 40 Europe Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 41 Europe Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 42 Europe Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 43 Europe Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 44 Europe Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 45 Europe Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 46 Europe Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 47 Europe Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 48 Europe Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 49 Europe Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 50 Europe Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 51 Europe Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 52 Europe Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 53 Europe Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 54 Europe Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 55 Asia Pacific Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 56 Asia Pacific Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 57 Asia Pacific Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 58 Asia Pacific Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 59 Asia Pacific Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 60 Asia Pacific Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 61 Asia Pacific Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 62 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 63 Asia Pacific Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 64 Asia Pacific Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 65 Asia Pacific Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 66 Asia Pacific Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 67 Asia Pacific Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 68 Asia Pacific Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 69 Asia Pacific Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 70 Asia Pacific Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 71 Asia Pacific Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 72 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 73 South America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 74 South America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 75 South America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 76 South America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 77 South America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 78 South America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 79 South America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 80 South America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 81 South America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 82 South America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 83 South America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 84 South America Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 85 South America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 86 South America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 87 South America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 88 South America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 89 South America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 90 South America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 91 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 92 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 93 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 94 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 95 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 96 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 97 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 98 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 99 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 100 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 101 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 102 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 103 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 104 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 105 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 106 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 107 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 108 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
| ※参考情報 神経免疫治療薬は、神経系と免疫系の相互作用をターゲットとした治療薬の総称です。これらの薬剤は、神経変性疾患や自己免疫疾患の治療において、免疫応答の調節を行うことで病状を改善することを目的としています。神経免疫学は、神経科学と免疫学を統合した分野であり、両者の相互関係を理解することが、神経疾患の新たな治療法の開発に繋がっています。 神経免疫治療薬の種類にはいくつかのカテゴリーがあります。第一に、抗体治療薬が挙げられます。これらは特定の免疫細胞やその成分を標的とし、過剰な免疫応答を抑制します。また、サイトカイン抑制剤も重要な役割を果たしています。サイトカインは免疫細胞の間での信号伝達を担う物質であり、これを抑制することで炎症反応を抑えます。 さらに、小分子化合物も神経免疫治療に利用されています。これらは細胞内のシグナル伝達経路を阻害したり、特定の酵素を標的としたりすることで、免疫系の異常な反応を調整します。加えて、免疫調整剤も神経免疫治療において重要です。これらは免疫系全体の働きを調整し、自己免疫疾患の進行を抑制します。 神経免疫治療薬の主な用途としては、自己免疫性疾患の治療が挙げられます。多発性硬化症、視神経脊髄炎、関節リウマチなどが代表的です。これらの疾患では、免疫系が自己の神経組織を攻撃し、様々な症状を引き起こします。神経免疫治療薬は、これらの症状を和らげ、疾患の進行を抑制することが期待されています。また、神経変性疾患、例えばアルツハイマー病やパーキンソン病においても、神経栄養因子や神経保護効果を持つ薬剤が研究されています。 神経免疫治療の関連技術としては、バイオマーカーの発見が重要です。バイオマーカーとは、疾患の進行や治療反応を評価するための指標となる生物学的な物質のことです。これにより、患者ごとの最適な治療法を選択することが可能になるため、個別化医療の推進にも寄与します。 さらに、遺伝子治療や細胞治療も新しいアプローチとして注目されています。これらの技術は、免疫系を再プログラムすることや、失われた神経機能を補うことを目的としています。特に、幹細胞を用いた治療が様々な神経疾患において研究が進められています。これにより、神経再生や修復が期待されています。 臨床試験においても、神経免疫治療薬の安全性や有効性が評価されています。新たな治療薬の開発には、動物モデルを用いた前臨床研究が不可欠であり、その後、ヒトを対象とした臨床試験が行われます。これにより、治療の効果を確認し、最終的には医療現場における新たな選択肢として患者に提供されることになります。 総じて神経免疫治療薬は、神経系と免疫系の複雑な相互作用に基づいた新たな治療法の探求を象徴しています。今後、より多くの疾患に対する効果的な治療薬の登場が期待されており、これにより多くの患者の生活の質が向上することが望まれています。神経免疫系の研究は、新しい治療戦略を生むための鍵となるものであり、この分野の進展に対する期待は高まるばかりです。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
